NCT00043368

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

Conditions

• Melanoma
• Breast Neoplasms
• Carcinoma, Renal Cell
• Lymphoma, T-Cell
• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	PF-3512676	PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.

Timeline

• Start date: 2002-09-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2002-08-12
• Last updated: 2009-03-12

Locations

32 sites across 2 countries: United States, Germany